Shareholder Alert: Ademi LLP investigates whether Intersect ENT, Inc. has obtained a Fair Price in its transaction with Medtronic

MILWAUKEE, Aug. 6, 2021 /PRNewswire/ -- Ademi LLP is investigating Intersect ENT (NASDAQ: XENT) for possible breaches of fiduciary duty and other violations of law in its transaction with Medtronic.

Click here to learn how to join the action: https://www.ademilaw.com/case/intersect-ent-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges Intersect ENT's financial outlook and prospects are excellent and yet Intersect ENT shareholders will receive only $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion. The merger agreement unreasonably limits competing bids for Intersect ENT by prohibiting solicitation of further bids, and imposing a substantial penalty if Intersect ENT accepts a superior bid. Intersect ENT insiders will receive millions of dollars as part of change of control arrangements. We are investigating the conduct of Intersect ENT's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Intersect ENT.

If you own Intersect ENT common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/intersect-ent-inc.                        

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-intersect-ent-inc-has-obtained-a-fair-price-in-its-transaction-with-medtronic-301350257.html

SOURCE Ademi LLP